CLINICAL TRIALS PROFILE FOR PINDOLOL

All Clinical Trials for Pindolol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00149110 ↗	Chronos: the Use of Chronobiological Treatment in Depression	Completed	Eli Lilly and Company	N/A	2005-09-01	The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.

Clinical Trial Conditions for Pindolol

Condition Name

Condition Name for Pindolol
Intervention	Trials
Major Depression	3
Healthy	2
Heart Disease	2

Condition MeSH

Condition MeSH for Pindolol
Intervention	Trials
Depressive Disorder	7
Depression	6
Depressive Disorder, Major	5

Clinical Trial Locations for Pindolol

Trials by Country

Trials by Country for Pindolol
Location	Trials
United States	17
Denmark	4
Spain	2
Switzerland	2
Canada	1

Trials by US State

Trials by US State for Pindolol
Location	Trials
New York	3
Florida	2
California	2
North Carolina	1
Maryland	1

Clinical Trial Progress for Pindolol

Clinical Trial Phase

Clinical Trial Phase for Pindolol
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Pindolol
Clinical Trial Phase	Trials
Completed	7
Terminated	4
Enrolling by invitation	2

Clinical Trial Sponsors for Pindolol

Sponsor Name

Sponsor Name for Pindolol
Sponsor	Trials
Hillerod Hospital, Denmark	2
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	2
Weill Medical College of Cornell University	2

Sponsor Type

Sponsor Type for Pindolol
Sponsor	Trials
Other	26
Industry	8
NIH	4

Pindolol: Clinical Trials, Market Analysis, and Projections

Introduction

Pindolol, a β-adrenoceptor antagonist, has been a significant player in the pharmaceutical industry for decades, primarily used in the treatment of various cardiovascular and nervous system disorders. Here, we delve into the current state of clinical trials, market analysis, and future projections for this drug.

Mechanism of Action and Clinical Uses

Pindolol acts by targeting β-adrenoceptors, regulating the activity of the sympathetic nervous system. This mechanism makes it effective in treating conditions such as hypertension, arrhythmias, cardiac issues, angina pectoris, and tachycardia[3].

Clinical Trials Update

Antidepressant Augmentation

One notable area of research involves the use of pindolol to augment the effects of selective serotonin reuptake inhibitors (SSRIs) in treating depression. A double-blind, randomized, placebo-controlled trial examined the efficacy of adding pindolol to previous ineffective SSRI treatments. The results showed no significant differences in the severity of depression between the pindolol and placebo groups, as measured by HAM-D and MADRS scores[1].

Cancer-Related Cachexia

A recent development involves the use of S-pindolol benzoate in treating cachexia, a wasting disease associated with cancer. Phase 2b/3 trials have been approved to evaluate S-pindolol benzoate for treating cachexia in patients with colorectal and non-small cell lung cancer. Preliminary phase 2a trials showed promising results, demonstrating the drug's anti-catabolic and pro-anabolic pharmacology[4].

Market Analysis

Current Market Size and Growth

Pindolol is part of the broader cardiovascular and nervous system drug market. While specific market data for pindolol alone is not readily available, the overall market for cardiovascular drugs is substantial. For instance, the endocrinology drugs market, which includes some cardiovascular treatments, is expected to grow from $35.05 billion in 2024 to $53.85 billion by 2030, with a CAGR of 7.34%[2].

Market Drivers

• Increasing Prevalence of Cardiovascular Disorders: The growing prevalence of cardiovascular diseases, partly due to an aging population and lifestyle changes, drives the demand for drugs like pindolol.
• Innovation in Drug Formulations: Advances in drug formulations, such as long-acting and biologic drugs, contribute to market growth.
• Integration of Digital Health Technologies: The integration of digital health technologies to enhance personalized treatment also boosts market expansion[2].

Market Restraints

• High Development Costs: The high cost associated with the research and development of new drugs, including pindolol derivatives, can be a significant barrier.
• Stringent Regulatory Requirements: Strict regulatory requirements can delay product launches and impact market growth.
• Price Sensitivity and Generic Competition: Price sensitivity and competition from generic drugs also pose challenges[2].

Market Projections

Future Development Opportunities

• Gene Therapy and CRISPR Applications: Innovations in gene therapy and CRISPR applications offer potential avenues for significant advancements in the treatment of conditions targeted by pindolol.
• Biosimilar Development: The development of biosimilars could provide more affordable alternatives and expand market reach.
• Emerging Markets: Improving healthcare infrastructure and increased healthcare spending in emerging markets present untapped potential for pindolol and its derivatives[2].

Competitive Landscape

Companies like Novartis AG, AstraZeneca PLC, GSK Plc, and C.H. Boehringer Sohn AG & Co. KG are key players in the development of β-adrenoceptor antagonists, including pindolol. These companies are driving innovation and competition in the market[3].

Key Takeaways

• Pindolol continues to be used in various clinical settings, particularly for cardiovascular and nervous system disorders.
• Ongoing clinical trials, such as those for S-pindolol benzoate in treating cancer-related cachexia, show promising results.
• The market for cardiovascular and endocrinology drugs is expected to grow significantly, driven by increasing prevalence of diseases and innovations in drug formulations.
• High development costs, stringent regulatory requirements, and generic competition are key challenges.
• Future opportunities lie in emerging markets, personalized medicine, and advancements in biotechnology.

FAQs

What is the primary mechanism of action of pindolol?

Pindolol acts by targeting β-adrenoceptors, regulating the activity of the sympathetic nervous system, which is responsible for the "fight or flight" response[3].

What are the current clinical trials focusing on pindolol?

Current trials include the use of S-pindolol benzoate to treat cachexia in patients with colorectal and non-small cell lung cancer, as well as studies on augmenting the effects of SSRIs in treating depression[1][4].

What are the market drivers for pindolol and similar drugs?

Market drivers include the increasing prevalence of cardiovascular disorders, innovation in drug formulations, and the integration of digital health technologies[2].

What are the main challenges facing the market for pindolol?

Challenges include high development costs, stringent regulatory requirements, and competition from generic drugs[2].

What future opportunities exist for pindolol and its derivatives?

Future opportunities include advancements in gene therapy, CRISPR applications, biosimilar development, and expansion into emerging markets[2].

Sources

1. A Double-blind, Randomized, Placebo-Controlled Trial of Pindolol ... - JAMA Psychiatry
2. Endocrinology Drugs Market Analysis by Therapy Area, Distribution Channel and Region - A Forecasted $53.85 Billion Industry by 2030 - GlobeNewswire
3. Exploring Pindolol's Revolutionary R&D Successes and its ... - Synapse
4. Phase 2B/3 Trial to Study Novel Drug for Cancer-Related Cachexia - CureToday